ATNM · Actinium Pharmaceuticals, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | $90.0K | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $4.20M | - | $4.25M | $4.88M | $7.70M | - | $9.77M | $8.82M | $6.63M | - |
| SG&A | $1.70M | - | $1.53M | $2.62M | $8.94M | - | $2.83M | $3.59M | $2.96M | - |
| Total Operating Expenses | $5.90M | - | $5.78M | $7.50M | $16.64M | - | $12.60M | $12.42M | $9.60M | - |
| D&A | $29.0K | - | - | - | $216.0K | - | - | - | $216.0K | - |
| Operating Income | ($5.90M) | - | ($5.69M) | ($7.50M) | ($16.64M) | - | ($12.60M) | ($12.42M) | ($9.60M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($5.52M) | - | ($5.13M) | ($6.88M) | ($15.94M) | - | ($11.57M) | ($11.35M) | ($8.67M) | - |
| EPS - Basic | ($0.18) | - | ($0.16) | ($0.22) | ($0.51) | - | ($0.37) | ($0.38) | ($0.31) | - |
| EPS - Diluted | ($0.18) | - | ($0.16) | ($0.22) | ($0.51) | - | ($0.37) | ($0.38) | ($0.31) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $42.13M | $48.00M | $53.39M | $59.93M | $65.33M | $72.90M | $78.66M | $86.04M | $84.06M | $76.68M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | - | - | - | - | - | - | - | - | - | - |
| Current Assets | $43.26M | $49.38M | $54.37M | $61.03M | $66.46M | $74.51M | $79.52M | $87.07M | $85.37M | $78.26M |
| Total Assets | $45.44M | $51.77M | $56.15M | $63.02M | $68.65M | $76.90M | $82.11M | $89.86M | $88.35M | $81.44M |
| Current Liabilities | $7.35M | $7.97M | $6.83M | $8.31M | $7.11M | $8.15M | $7.75M | $9.73M | $8.06M | $8.49M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $43.13M | $43.94M | $42.37M | $44.00M | $42.95M | $44.14M | $43.91M | $46.03M | $44.49M | $45.07M |
| Stockholders' Equity | $2.30M | $7.83M | $13.78M | $19.01M | $25.69M | $32.76M | $38.21M | $43.84M | $43.86M | $36.38M |
| Retained Earnings | ($415.24M) | ($409.71M) | ($403.77M) | ($398.64M) | ($391.76M) | ($375.83M) | ($369.17M) | ($357.61M) | ($346.25M) | ($337.58M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($5.87M) | - | - | - | ($7.57M) | - | - | - | ($7.37M) | - |
| Investing Cash Flow | ($2.0K) | - | - | - | - | - | - | - | ($11.0K) | - |
| Financing Cash Flow | ($3.0K) | - | - | - | ($2.0K) | - | - | - | $14.77M | - |
| CapEx | $2.0K | - | - | - | - | - | - | - | $11.0K | - |
| Free Cash Flow | ($5.87M) | - | - | - | - | - | - | - | ($7.38M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | -6324.4% | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | -5701.1% | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 1.06 | - | - | - | - | - | - | - | 0.85 | - |
| R&D / Revenue | - | - | 4720.0% | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | 1704.4% | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -12.2% | - | -9.1% | -10.9% | -23.2% | - | -14.1% | -12.6% | -9.8% | - |
| Return on equity | -239.7% | - | -37.2% | -36.2% | -62.0% | - | -30.3% | -25.9% | -19.8% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 5.89 | 6.20 | 7.96 | 7.34 | 9.35 | 9.14 | 10.25 | 8.95 | 10.59 | 9.21 |
| Quick ratio | 5.89 | 6.20 | 7.96 | 7.34 | 9.35 | 9.14 | 10.25 | 8.95 | 10.59 | 9.21 |
| Cash ratio | 5.73 | 6.02 | 7.81 | 7.21 | 9.19 | 8.95 | 10.14 | 8.84 | 10.42 | 9.03 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 19.72 | 6.61 | 4.07 | 3.31 | 2.67 | 2.35 | 2.15 | 2.05 | 2.01 | 2.24 |
| Liabilities / Assets | 0.95 | 0.85 | 0.75 | 0.70 | 0.63 | 0.57 | 0.53 | 0.51 | 0.50 | 0.55 |
| Efficiency | ||||||||||
| Asset turnover | - | - | 0.00 | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | 26.0% | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 64.5% | - | 54.8% | 39.6% | -73.4% | - | 12.2% | 20.6% | 17.2% | - |
| Net income growth (YoY) | 65.4% | - | 55.6% | 39.4% | -83.8% | - | 12.9% | 25.2% | 21.4% | - |
| EPS growth (YoY) | 64.7% | - | 56.8% | 42.1% | -64.5% | - | 24.5% | 34.5% | 27.9% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | 51.3% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -91.0% | -76.1% | -63.9% | -56.6% | -41.4% | -10.0% | -12.3% | -17.4% | -23.3% | -45.3% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$90.0K totalOther Revenue$90.0K · 100.0%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Actinium Pharmaceuticals against the 5 most active filers in the same SIC group.